This company has been marked as potentially delisted and may not be actively trading. (BIOA) (BIOA) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipTrendsBuy This Stock BIOA vs. XERS, IMNM, RCKT, XNCR, ABUS, AVBP, BCAX, DNTH, PRAX, and KALVShould you be buying (BIOA) stock or one of its competitors? The main competitors of (BIOA) include Xeris Biopharma (XERS), Immunome (IMNM), Rocket Pharmaceuticals (RCKT), Xencor (XNCR), Arbutus Biopharma (ABUS), ArriVent BioPharma (AVBP), Bicara Therapeutics (BCAX), Dianthus Therapeutics (DNTH), Praxis Precision Medicines (PRAX), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical preparations" industry. (BIOA) vs. Xeris Biopharma Immunome Rocket Pharmaceuticals Xencor Arbutus Biopharma ArriVent BioPharma Bicara Therapeutics Dianthus Therapeutics Praxis Precision Medicines KalVista Pharmaceuticals Xeris Biopharma (NASDAQ:XERS) and (BIOA) (NYSE:BIOA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership. Do analysts recommend XERS or BIOA? Xeris Biopharma presently has a consensus price target of $6.10, indicating a potential upside of 48.42%. (BIOA) has a consensus price target of $5.67, indicating a potential upside of 46.61%. Given Xeris Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Xeris Biopharma is more favorable than (BIOA).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80(BIOA) 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Is XERS or BIOA more profitable? (BIOA) has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Company Net Margins Return on Equity Return on Assets Xeris Biopharma-33.69% N/A -17.38% (BIOA) N/A N/A N/A Which has preferable earnings and valuation, XERS or BIOA? (BIOA) has lower revenue, but higher earnings than Xeris Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXeris Biopharma$203.07M3.12-$62.26M-$0.38-10.82(BIOA)N/AN/AN/AN/AN/A Does the media prefer XERS or BIOA? In the previous week, Xeris Biopharma had 8 more articles in the media than (BIOA). MarketBeat recorded 8 mentions for Xeris Biopharma and 0 mentions for (BIOA). Xeris Biopharma's average media sentiment score of 1.11 beat (BIOA)'s score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Overall Sentiment Xeris Biopharma Positive (BIOA) Neutral Does the MarketBeat Community prefer XERS or BIOA? (BIOA) received 144 more outperform votes than Xeris Biopharma when rated by MarketBeat users. Likewise, 72.03% of users gave (BIOA) an outperform vote while only 70.00% of users gave Xeris Biopharma an outperform vote. CompanyUnderperformOutperformXeris BiopharmaOutperform Votes14770.00% Underperform Votes6330.00% (BIOA)Outperform Votes29172.03% Underperform Votes11327.97% Do institutionals & insiders have more ownership in XERS or BIOA? 42.8% of Xeris Biopharma shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryXeris Biopharma beats (BIOA) on 8 of the 12 factors compared between the two stocks. Get (BIOA) News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOA vs. The Competition Export to ExcelMetric(BIOA)Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$161.32M$6.46B$5.31B$18.42BDividend YieldN/A3.22%5.47%4.18%P/E RatioN/A6.9521.9431.09Price / SalesN/A231.01380.9426.53Price / CashN/A65.6738.3117.52Price / BookN/A5.936.454.30Net IncomeN/A$143.22M$3.22B$1.02B (BIOA) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOA(BIOA)N/A$3.87-16.7%$5.67+46.6%+30,095.3%$161.32MN/A0.00N/AXERSXeris Biopharma4.2288 of 5 stars$4.16flat$6.10+46.6%+136.2%$640.39M$203.07M-9.24290Short Interest ↑News CoveragePositive NewsIMNMImmunome2.5757 of 5 stars$7.35+3.5%$25.14+242.1%-48.9%$639.09M$9.04M-0.9140Positive NewsRCKTRocket Pharmaceuticals4.6212 of 5 stars$5.91+12.1%$43.00+627.6%-72.2%$630.18MN/A-2.15240News CoveragePositive NewsHigh Trading VolumeXNCRXencor3.4852 of 5 stars$8.94+4.7%$34.38+284.5%-47.2%$629.93M$110.49M-2.79280News CoverageABUSArbutus Biopharma1.9619 of 5 stars$3.28+4.5%$5.50+67.7%+15.8%$628.05M$6.17M-7.6390Positive NewsAVBPArriVent BioPharma1.1826 of 5 stars$18.39+1.3%$39.00+112.1%+17.0%$625.55MN/A-7.1640BCAXBicara TherapeuticsN/A$11.38+5.7%$36.50+220.8%N/A$620.47MN/A0.0032Analyst ForecastNews CoverageGap UpDNTHDianthus Therapeutics2.1005 of 5 stars$18.71+6.2%$54.33+190.4%-16.1%$601.06M$6.24M-7.4880News CoveragePositive NewsPRAXPraxis Precision Medicines3.1151 of 5 stars$29.75+0.0%$123.33+314.6%-27.9%$599.85M$8.55M-2.89110News CoveragePositive NewsGap UpKALVKalVista Pharmaceuticals4.2417 of 5 stars$11.95+4.0%$24.83+107.8%+3.7%$594.11MN/A-3.28100Gap Up Related Companies and Tools Related Companies Xeris Biopharma Alternatives Immunome Alternatives Rocket Pharmaceuticals Alternatives Xencor Alternatives Arbutus Biopharma Alternatives ArriVent BioPharma Alternatives Bicara Therapeutics Alternatives Dianthus Therapeutics Alternatives Praxis Precision Medicines Alternatives KalVista Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BIOA) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BIOA) Please log in to your account or sign up in order to add this asset to your watchlist. Share (BIOA) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
